Neurological manifestations and etiological risk factors in patients hospitalized with COVID-19 in Turkey

Creative Commons License

Usta N. C., Kartal S., Gunay B. O., BOZ C.

Asian Biomedicine, cilt.16, sa.1, ss.23-30, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2478/abm-2022-0004
  • Dergi Adı: Asian Biomedicine
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, Veterinary Science Database
  • Sayfa Sayıları: ss.23-30
  • Anahtar Kelimeler: COVID-19, neurological manifestations, SARS-CoV-2, seizure, Turkey
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

© 2022 Nuray Can Usta et al., published by Sciendo.Background: Coronavirus disease 2019 (COVID-19) can affect the neurological as well as the respiratory system. Neurological manifestations may involve the central or peripheral nervous systems, or musculoskeletal system. Findings can range from mild presentations, such as headache and anosmia, to severe complications, such as stroke and seizure. Objectives: To evaluate the neurological findings and to determine etiological risk factors for mortality in patients hospitalized for COVID-19. Methods: Medical records of patients with COVID-19 who were hospitalized and sought neurological consultation between March 2020 and March 2021 at a reference pandemic hospital in Turkey were reviewed retrospectively in a cross-sectional study design. Result: We included data from 150 (94 male) patients. Their mean age ± standard deviation was 68.56 ± 16.02 (range 21-97) years. The patients were categorized into 2 groups according to any acute neurological event or progression of neurological disease. Ischemic cerebrovascular events, seizures, and encephalopathy were the most common acute neurological events, while deterioration in consciousness, epileptic seizures, and Parkinson disease were observed in those with progression of neurological disease. Abnormal neurological findings were found at a mean of 7.8 ± 9.7 days following COVID-19 diagnosis and 50 (a third of) patients died. A logistic regression model found that advanced age, increased Modified Charlson Comorbidity Index (MCCI) score, and prolonged duration of hospitalization were factors significantly associated with increased mortality; however, sex and day of abnormal neurological findings after COVID-19 diagnosis were not. Common conditions accompanying neurological events were hypertension, coronary artery disease-heart failure, and diabetes mellitus. Conclusion: COVID-19 may present with neurological symptoms in our Turkish patients and comorbidities are often present.